[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100619810":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":29,"centralContacts":38,"locations":44,"responsibleParty":58,"collaborators":29,"id":62,"slug":29,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":29,"eligibilityCriteria":67,"healthyVolunteers":63,"sex":68,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":29,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":83,"overallStatus":87,"whyStopped":29,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"Tanta University","OTHER",[8,14,20],{"label":9,"type":10,"description":11,"interventionNames":12},"Group 1 (Doxorubicin group)","PLACEBO_COMPARATOR","30 patients will receive a traditional chemotherapeutic agent (Doxorubicin group) for 12 weeks.",[13],"Drug: Group 1 (Doxorubicin group)",{"label":15,"type":16,"description":17,"interventionNames":18},"Group 2 (Vitamin D group)","EXPERIMENTAL","patients with Vitamin D supplementation (1000 iu\u002Fday) plus Doxorubicin for 12 weeks",[19],"Drug: Group 2: Vitamin D group",{"label":21,"type":16,"description":22,"interventionNames":23},"Group 3 (melatonin group)","30 patients with 10 mg of melatonin orally, once daily plus Doxorubicin for 12 weeks.",[24],"Drug: Group 3: melatonin group",[26,30,34],{"type":27,"name":9,"description":11,"armGroupLabels":28,"otherNames":29},"DRUG",[9],null,{"type":27,"name":31,"description":32,"armGroupLabels":33,"otherNames":29},"Group 2: Vitamin D group","patients with Vitamin D supplementation (1000 iu\u002Fday) plus traditional therapy for 12 weeks",[15],{"type":27,"name":35,"description":36,"armGroupLabels":37,"otherNames":29},"Group 3: melatonin group","patients with 10 mg of melatonin orally, once daily plus traditional therapy for 12 weeks",[21],[39],{"name":40,"role":41,"phone":42,"phoneExt":29,"email":43},"Majed Alharbi, Resident","CONTACT","+966 55 189 8178","Ph.majed33@gmail.com",[45],{"facility":5,"status":29,"city":46,"state":29,"zip":29,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Tanta","Egypt","EG",{"type":50,"coordinates":51},"Point",[52,53],31.00192,30.78847,{"lat":53,"lon":52},[56],{"name":57,"role":41,"phone":42,"phoneExt":29,"email":43},"Majed Essa Alharbi, Resident",{"type":59,"investigatorFullName":60,"investigatorTitle":61,"investigatorAffiliation":5,"oldNameTitle":29,"oldOrganization":29},"PRINCIPAL_INVESTIGATOR","Majed Essa Alharbi","Resident","100619810",false,"NCT07349459","Cardioprotective Effect of Melatonin Versus Vitamin D in Breast Cancer Patients Receiving Doxorubicin","Clinical Study Evaluating Cardioprotective Effect of Melatonin Versus Vitamin D in Breast Cancer Patients Receiving Doxorubicin","Inclusion Criteria:\n\n* Age from 18 to 65 years old.\n* Gender: female.\n* Positive breast cancer women who are scheduled to receive Doxorubicin.\n* Have a good performance status according to the eastern cooperative oncology group with a score of 0-2.\n* Normal baseline Echocardiography with left ventricular ejection fraction ≥ 50%.\n* Normal renal and liver function tests.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women.\n* Women with HER-2 positive of breast cancer.\n* Formerly treated with Doxorubicin.\n* Patients with a known hypersensitivity to any of the used drugs.\n* On other concomitant vitamins or food supplements.\n* Valvular heart disease, coronary artery disease, history of congestive heart failure or cardiomyopathy.\n* Impaired Left ventricular systolic function in which the Left Ventricular Ejection Fraction \\\u003C 50%.","FEMALE","18 Years","65 Years",{"count":72,"type":73},90,"ESTIMATED","INTERVENTIONAL",[76],"NA","This study aims to assess the cardioprotective effect of melatonin and vitamin D in breast cancer patients who receive doxorubicin.",[79,80,81,82],"Melatonin","Breast Cancer Patients Diagnosed","Vitamin D Concentration","Doxorubicin",[84,82,85,79,86],"Vitamin D","Cardioprotective Effect","Breast Cancer Patients","NOT_YET_RECRUITING","2026-01-09",{"date":90,"type":91},"2026-01-16","ACTUAL",{"date":93,"type":73},"2026-04-30",{"date":95,"type":73},"2026-08-30",{"name":5,"class":6},1]